PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to		tion unless it contains a valid QMB control number
Substitute for form 1449/PTO	Co	mplete if Known
	Application Number	
INFORMATION DISCLOSURE	Filing Date	
	First Named Inventor	Albrecht
STATEMENT BY APPLICANT	Art Unit	
(Use as many sheets as necessary)	Examiner Name	
Sheet 1 of 3	Attorney Docket Number	BJA319A

	1			DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (F Angular)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US. 4 000 057	00.40.4004	Barrier at all all and a second	
		^{US-} 4,992,257	02-12-1991	Bonnett et al	
		^{US-} 5,162,519	11-10-1992	Bonnett et al	1
		US-			
		US-	1		
		US-			1
		US-			
		US-			1
		US-			
		US-			
		US-			
		US-	1	1	
		US-			

	FOREIGN PATENT DOCUMENTS							
		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages					
inidats	140.	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear	Τ6		
	1		1					
	_							
	Ι.				1			

Examiner	Date	
Signature	Considered	
Organization	OU. MILCIEG	i e

"EXAMINER: Initial if reference considered, whether or not claiton is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Initiade copy of this form with next communication to applicant. Applicants are unique citation designation number (optional). "See Kinst Socies of USPTO Patent Decements at www.userloop.copy or MPEP 901 ob.". Enter Office that issued the document, by the two-level code (WIPD Standard ST.3)." For Jupanese patent documents, he indication of the year of the region of the Emperor must precede the serial number of the patent document. "Aind of document the appropriate symbols as indication of on the document under WIPD Standard ST.1 for passible." Applicant is to place and each mark here light integrated and the specifical symbols as indication of on the document under WIPD Standard ST.1 for passible. "Applicant is to place and each mark here light integrated and the specifical symbols as indication of on the document under WIPD Standard ST.1 for passible." Applicant is to place and each mark here light integrated and the specifical symbols as indication on the document under WIPD Standard ST.1 for passible. "Applicant its to place and each mark here light integrated and the specifical symbols and the specifical symbols as indication of an extreme symbol."

Inasiation is attached.

This solded in of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 33 U.S.C. 122 and 37 CFR 1.14. This collection is closed to take 2 hours to complete moduling gathering property, and solderning the completed application from to the USPTO. These where year of the service of the amount of time you require to complete into the sum and/or suggestions for reducing his burden, should be sent to the Chief Information Officer. U.S. Patient and Toddmank Officer, P.O., Box 1469, Alexandris, N.Y. 2311-4450, D. OHO VISEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SSND TO. Commissioner for Patient, P.O. Box 1469, Alexandris, N.Y. 2311-4450, D. OHO VISEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SSND TO. Commissioner for Patient, P.O. Box 1469, Alexandris, N.Y. 2311-4450, D. OHO VISEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SSND TO. Commissioner for Patient, P.O. Box 1469, Alexandris, N.Y. 2311-4450, D. OHO VISEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SSND TO. Commissioner for Patient, P.O. Box 1469, Alexandris, N.Y. 2311-4450, D. OHO VISEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SSND TO. Commissioner for Patient, P.O. Box 1469, Alexandris, N.Z. 2311-4450, D. OHO VISEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SSND TO. Commissioner for Patient, P.O. Box 1469, Alexandris, N.Z. 2311-4450, D. OHO VISEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SSND TO THE ADDRESS TO THE PATIENT TO THE PATIENT

Approved for use through 66/30/2006. OMB 055-10/31.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a wait of OMB control number.

Substitute for form 1449B/PTO						Complete if Known	
					Application Number		
	INFO	RMATION D	ISCLO	SURE	Filing Date		
STATEMENT BY APPLICANT			CANT	First Named Inventor	Albrecht		
					Art Unit		
		(Use as many sheets a:	s necessary)	Examiner Name		
$\overline{}$	Sheet	2	of	3	Attorney Docket Number	BJA319A	

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher				
		DASS et al, "Enhanced Anticancer Therapy Mediated by Specialized Liposomes", J. Pharm. Pharmacol. 1997, 972-75				
		STORM et al, "Liposomes: quo vadis?", Pharm. Science & Tech. Today, April 1998, 19-31, v. 1, Elsevier Science				
	!	HARRIS et al, "Effect of Pegylation on Pharmaceuticals", Nature, March 2003, 214-221, v. 1, Nature Pub. Grp.				
		PAPAHADJOPOULOS et al, "Sterically stabilized liposomes: Imporvements in pharmacokinetics and antitumor therapeutic efficacy", Proc. Natl. Acad. Sci. USA, Dec 1991, 11460-64, v. 88				
		MUGGIA et al, "Phase II Study of Liposomal Doxorubicin in Refractory Ovarian Cancer: Antitumor Activity and Toxicity Modification by Liposomal Encapsulation", J. of Clinical Oncology, March 1997, 987-993, v. 15, no. 3				
		MODY et al, "Pharmaceutical development and medical applications of porphyrin-type macrocycles", Journal of Porphyrins & Phthalocyanines 2000, 362-367, v. 4 STERNBERG et al, "Porphyrin-based Photosensitizers for Use in Photodynamic Therapy, Tetrahedron 1998,4151-				
		4202, v. 54				

$\overline{}$			
Examiner		Date	1
Signature		Considered	,

*EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

"EAAMINEK: Initial in reterrick considered, whether or not catalon is in conformance with MPEP 909. Draw in the through calation in not in conformance and not considered, include copy of this form with met accommission in applicant.

1 Applicant's unique classion designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique classion designation number 10 3B. The information is required to obtain or retain a benefit by the public which is 618 (and by the USPTO) to process) an application. Confidentiality is governed by 3 SU.S.C. 122 and 37 CPR 1.14. This collection of indication is estimated to the same to complete including generating reporting, and subtiniting the completed application from the USPTO. The will vary depending upon the individual scale. Any comments on the amount of irms you retrieve to complete in the same of the control of the same of the control of the cont ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03) Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO						Complete if Known
					Application Number	
INFORMATION DISCLOSURE				SURE	Filing Date	
	STAT	EMENT BY A	APPLI	CANT	First Named Inventor	Albrecht
					Art Unit	
		(Use as many sheets as	necessary)	Examiner Name	
\subset	Sheet	3	of	3	Attorney Docket Number	BJA319A

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), title of the item (took, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, citly and/or country where published.	T ²
		DERYCKE et al, "Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-Liposomes", Intl. J. of Oncology 2002, 181-187, v. 20	
		WOODLE et al, "Sterically stabilized liposomes" Biochimica et Biophysica Acta 1992,171-199,v. 1113	
		VAAGE et al, "Therapy of Primary & Metastatic Mouse Mammary Carcinomas with Doxorubicin Encapsulated in Long Circulating Liposomes", Int. J. Cancer 1992, 942-948,v. 51	
		STEWART et al, "Randomized Comparative Trial of Pegyla Liposomal Doxorubicin Versus Bleomycin & Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma", J. of Clinical Oncology, Feb 1998, 683-691, v. 16, no. 2	ted
		NORTHFELT et al, "Pegylated-Liposomal Doxorubicin Vers Doxorubicin, Bleomycin, & Vincristine in the Treatmen of AIDS-Related Kaposi's Sarcoma: Results of a Randomized Phase III Clinical Trial", J. of Clinical Oncology, July 1998, 2445-2451, v. 16, no. 7	

Examiner	Date	
Signature	Considered	1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with mat communication in supplicimit.

1 Applicant's in Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CPR 1 37 and 1.38. The information is required to obtain or retain a behefit by the public which is to file (and by the UPPTO opposes) an application. Conformation is produced by 37 CPR 1.14. This collection is estimated to lake 2 hours to compilete. including gathering, preparing, and submitting the completed application for the USPTO. The will wary appearing, and submitting the comments on the amount of time you require to complete this form and/or suggestions for require to complete this form and/or suggestions for require building in the provided as each to the Complete this form and/or suggestions for require building in the provided as each to the Complete this form and/or suggestions for require building this building is building to sent to the COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.